These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37771317)

  • 21. Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases.
    Felice C; Pugliese D; Papparella LG; Pizzolante F; Onori E; Gasbarrini A; Rapaccini GL; Guidi L; Armuzzi A
    Expert Rev Clin Immunol; 2018 Sep; 14(9):751-759. PubMed ID: 30118354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey.
    Ellul P; Revés J; Abreu B; Chaparro M; Gisbert JP; Allocca M; Fiorino G; Barberio B; Zingone F; Pisani A; Cassar D; Michalopoulos G; Mantzaris G; Koutroubakis I; Karmiris K; Katsanos K; Ďuricova D; Burisch J; Madsen GR; Maaser C; Naila A; Orfanoudaki E; Milivojevic V; Buisson A; Avedano L; Leone S; Torres J
    J Crohns Colitis; 2022 Aug; 16(7):1070-1078. PubMed ID: 35037033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
    Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
    Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
    Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M
    Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy of the vaccination in inflammatory bowel disease.
    Carrera E; Manzano R; Garrido E
    World J Gastroenterol; 2013 Mar; 19(9):1349-53. PubMed ID: 23538553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination in Patients with Inflammatory Bowel Diseases.
    Manser CN; Maillard MH; Rogler G; Schreiner P; Rieder F; Bühler S;
    Digestion; 2020; 101 Suppl 1(Suppl 1):58-68. PubMed ID: 31968344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
    Khan N; Mahmud N
    Gastroenterology; 2021 Sep; 161(3):827-836. PubMed ID: 34048782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Wils P; Seksik P; Stefanescu C; Nancey S; Allez M; Pineton de Chambrun G; Altwegg R; Gilletta C; Vuitton L; Viennot S; Serrero M; Fumery M; Savoye G; Collins M; Goutorbe F; Brixi H; Bouguen G; Tavernier N; Boualit M; Amiot A; Abitbol V; Laharie D; Pariente B;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):460-470. PubMed ID: 33345331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines.
    Jones JL; Tse F; Carroll MW; deBruyn JC; McNeil SA; Pham-Huy A; Seow CH; Barrett LL; Bessissow T; Carman N; Melmed GY; Vanderkooi OG; Marshall JK; Benchimol EI
    Gastroenterology; 2021 Aug; 161(2):681-700. PubMed ID: 34334167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease.
    Nguyen HT; Minar P; Jackson K; Fulkerson PC
    World J Gastroenterol; 2017 Nov; 23(42):7644-7652. PubMed ID: 29204064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
    Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
    Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
    Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
    J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.
    Zacharopoulou E; Orfanoudaki E; Tzouvala M; Tribonias G; Kokkotis G; Kitsou V; Almpani F; Christidou A; Viazis N; Mantzaris GJ; Tsafaridou M; Karmiris K; Theodoropoulou A; Papathanasiou E; Zampeli E; Michopoulos S; Tigkas S; Michalopoulos G; Laoudi E; Karatzas P; Mylonas I; Kyriakos N; Liatsos C; Kafetzi T; Theocharis G; Taka S; Panagiotopoulou K; Koutroubakis IE; Bamias G
    Inflamm Bowel Dis; 2023 Feb; 29(2):228-237. PubMed ID: 35394529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ideal vaccination strategy in inflammatory bowel disease].
    Lee CK
    Korean J Gastroenterol; 2015 Mar; 65(3):159-64. PubMed ID: 25797379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
    Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
    Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next-Generation Therapeutics for Inflammatory Bowel Disease.
    Dulai PS; Sandborn WJ
    Curr Gastroenterol Rep; 2016 Sep; 18(9):51. PubMed ID: 27461274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis.
    Novello M; Stocchi L; Holubar S; Shawki S; Lipman J; Gorgun E; Hull T; Steele SR
    Int J Colorectal Dis; 2019 Mar; 34(3):451-457. PubMed ID: 30535559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.